BOSTON, Aug 11 (Reuters) -- U.S. regulators refused to approve an experimental drug to treat gout being developed by Abbott Laboratories Inc. (ABT.N: Quote, Profile, Research) and Takeda Pharmaceuticals Co. (4502.T: Quote, NEWS, Research), according to a regulatory filing.
